In a remarkable leap forward for obesity treatment, Eli Lilly has revealed significant strides with orforglipron, an innovative oral GLP-1 receptor agonist targeting both obesity and diabetes. The announcement on August 26 showcases results from a pivotal Phase 3 clinical trial that have ignited
Imagine a condition so rare and devastating that it not only compromises the body’s ability to repair DNA but also skyrockets the risk of cancer by 500 to 700 times compared to the general population, a reality for individuals with Fanconi anemia (FA). This genetic disorder often leads to bone
I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, as well as a deep understanding of technology and innovation in the industry. Today, we’re diving into the heartbreaking case of Leticia Paul, a young lawyer who
We’re sitting down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research, development, and cutting-edge technology within the industry. With a career dedicated to pushing the boundaries of innovation, Ivan offers a unique perspective on how science and tech intersect
Imagine a political landscape where access to health care hinges on the drawing of district lines, a scenario unfolding right now as advocacy groups and lawmakers clash over congressional maps in a heated battle for influence. With reproductive rights and health funding under threat from
Imagine a world where life-saving treatments for cancer, autoimmune diseases, and metabolic disorders no longer require hours of intravenous infusions in a clinical setting, allowing patients to administer their medications at home with a quick injection, reclaiming time and autonomy. This scenario
